Fenofibrate, a peroxisome proliferator-activated receptor α (PPAR-α) agonist, is extensively used in clinical practice for managing dyslipidemia (58) as it reduces hepatic TG levels, although the mechanism underlying this effect in human subjects remains incompletely understood. The gene discussed is PPARA; the disease is metabolic syndrome.